September 23, 2021

The Roundup

Discover the latest English language news and information from

WHO calls for ban on 3rd dose, US rejects call

Posted on Wednesday 04 August 2021 at 21:39

“We urgently need to change things: the majority of vaccines go to rich countries, the majority to poor countries,” said Geneva Tetros Adonom Caprais, director of the World Health Organization (WHO).

In France, the “vaccination booster” against Covit-19 should begin “in early September” for people vaccinated in January and February, “as announced on July 12 by Republican leader Emmanuel Macron, without specifying the exact outline.” Week “, the Ministry of Health announced on Tuesday, August 2.

For their part, Germany and Israel have already announced campaigns for a third dose for vaccines that require two initial doses. This “booster dose” is designed specifically for the elderly, and despite its vaccination the immune system does not always produce enough antibodies.

In the wake of these announcements, the WHO on Wednesday called for a ban on the booster dose in an effort to restore equilibrium in the face of the gap between rich countries and poorer countries where covid vaccines are high. Vaccinate only a small portion of their population.

“We urgently need to change things: the majority of vaccines go to rich countries, the majority to poor countries,” said Geneva Tetros Adonom Caprais, director of the World Health Organization (WHO).

In May, the head of the UN agency called for an effort to extend his goal to “at least until the end of September”: 10% of the world’s population was vaccinated with Covid-19, which has officially killed more than 4.2 million since the end of 2019.

READ  Climate that the Gulf countries could not survive due to global warming - West-France evening edition

Promote the Kovacs system

“We need the cooperation of all to get there, especially some countries and organizations that control global vaccine production.”

In particular, he called on drug groups to promote the Covax system, which was set up to help fight vaccine inequality and help 92 poorer countries vaccinate their people.

For now, Kovacs has been unable to carry out its mission due to a shortage of the drug and was only able to distribute a small portion of what was initially planned due to the inability to purchase the required vaccines or the supply was blocked. We have to fight the epidemic in India.

However, the organization was able to benefit from tens of millions of doses of the vaccine given in many countries — such as the United States or France and other European countries — or by a type that is not suitable for them.

Of the 4 billion paid worldwide, 80% went to high- and middle-income countries, while they make up less than 50% of the world’s population.

The United States rejects the call for a ban

Dr. Bruce Aylward, in-charge of Kovacs at the WHO, acknowledged that the end of September was an ambitious goal that would not be achieved if we continued at the current pace.

The United States has already rejected the ban, believing that there is no “choice” between giving its citizens a third dose or donating to poor countries.

Kate O’Brien, head of the WHO’s Vaccines, questioned the effectiveness of the 3rd drug for its part.

READ  "The war against the existence of an international alliance has increased the ranks of the Taliban."

“We don’t have complete evidence as to whether we need it or not,” he said.

Mentioned by Emmanuel Macron, the campaign is based on two views of the Scientific Council and the Vaccine Strategic Guidance Council (COSV), published in early July.

It is important for companies to “implement at an affordable price”

The WHO has asked companies to try another front: prices.

Pfizer and Moderna have produced the best ambassador RNA vaccines on the market in record time, increasing dose prices for the EU because they have adapted their sera to variations.

Mariangela Simao, who is in charge of accessing drugs at the WHO, recalled that “it is very important for companies to train at affordable prices.”

“In a normal market environment, prices should fall, not increase,” he said, recalling that both Pfizer and Moderna have succeeded not only in increasing their productivity but also in productivity.

“We urge you to keep these companies affordable and affordable,” he stressed.